Moleculin Biotech, Inc.(MBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MBRX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Moleculin Biotech, Inc. (MBRX), a Healthcare sector company. MBRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of MBRX by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. MBRX trades on the Nasdaq exchange and files with the SEC under CIK 1659617. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moleculin Biotech, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-7.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-28.8% YoYOperating Income
+5.8% YoYTotal Assets
+30.7% YoYOp. Cash Flow
+4.7% YoYFree Cash Flow
+4.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-33.6M -28.8% | $-26.0M +12.5% | $-29.8M -2.6% | $-29.0M -82.6% | $-15.9M +8.4% | $-17.4M |
| Operating Income | $-25.1M +5.8% | $-26.6M +10.1% | $-29.6M +3.3% | $-30.6M -33.4% | $-23.0M -16.3% | $-19.7M |
| Total Assets | $22.1M +30.7% | $16.9M -55.7% | $38.2M -33.4% | $57.4M -31.7% | $84.1M +189.7% | $29.0M |
| Operating Cash Flow | $-22.7M +4.7% | $-23.9M -1.1% | $-23.6M +14.6% | $-27.6M -45.8% | $-19.0M -6.6% | $-17.8M |
| Free Cash Flow | $-22.7M +4.8% | $-23.9M -0.7% | $-23.7M +14.4% | $-27.7M -46.1% | $-19.0M -4.5% | $-18.1M |
Get alerted when MBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Moleculin Biotech, Inc. including:
Top Institutional Holders of MBRX
GEODE CAPITAL MANAGEMENT, LLC
$131.8K47,252 shVANGUARD CAPITAL MANAGEMENT LLC
$117.8K42,215 shVANGUARD FIDUCIARY TRUST CO
$83.4K29,883 shXTX Topco Ltd
$64.0K22,942 shMORGAN STANLEY
$55.9K20,036 shRockefeller Capital Management L.P.
$41.9K15,000 shTower Research Capital LLC (TRC)
$9.8K3,514 shCITIGROUP INC
$7.5K2,674 shBARCLAYS PLC
$1.7K621 shBlackRock, Inc.
$1.4K491 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $131.8K | 47,252 |
| VANGUARD CAPITAL MANAGEMENT LLC | $117.8K | 42,215 |
| VANGUARD FIDUCIARY TRUST CO | $83.4K | 29,883 |
| XTX Topco Ltd | $64.0K | 22,942 |
| MORGAN STANLEY | $55.9K | 20,036 |
| Rockefeller Capital Management L.P. | $41.9K | 15,000 |
| Tower Research Capital LLC (TRC) | $9.8K | 3,514 |
| CITIGROUP INC | $7.5K | 2,674 |
| BARCLAYS PLC | $1.7K | 621 |
| BlackRock, Inc. | $1.4K | 491 |
More Healthcare Companies
View all Healthcare →Put MBRX on your watchlist
Track score changes the day Moleculin Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MBRX a good stock to buy?
13F Pro's AI-powered analysis of Moleculin Biotech, Inc. (MBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBRX are available on the MBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MBRX is classified as a small company.
Which hedge funds own MBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Moleculin Biotech, Inc.'s investment landscape.